Vascular calcification is not just a deposit of salts but an active cellular process in which vascular smooth muscle cells (VSMCs) change their phenotype: they lose contractile proteins and start expressing genes typical of bone tissue. Alongside this work, the archive holds studies on cell plasticity and epigenetic regulation: how vibration wakes up crystals in a melt, how each cell ages along a methylation landscape, how a courier enzyme sets the pace in a dense gel. All of them deal with how external stimuli change the internal program of a cell or a material. This paper stands apart: its closest neighbor in meaning is a study on the secret of muscle contraction, but that one is about the physics of tiny magnets, not epigenetics. Here, for the first time, the changing composition of chromatin-remodeling complexes is traced in detail during the early stages of VSMC calcification.
Human VSMCs were cultured in medium with elevated calcium and phosphate to induce mineralization. Stages of calcification were determined by alizarin red staining and quantitative calcium analysis. The composition of SWI/SNF complexes was studied using immunoprecipitation followed by mass spectrometry (IP-MS). The genomic distribution of BRD9 and BRG1 was mapped by Cut&Run-Seq. To test the role of individual proteins, siRNA knockdown and a chemical BRD9 inhibitor (I-BRD9) were used. Single-nucleus RNA sequencing data from human atherosclerotic arteries were taken from a public dataset, and spatial transcriptomics came from carotid plaque samples. Immunohistochemistry was performed on human aortic sections.
BRD9 expression rose already at the pre-osteogenic stage (48 hours after stimulation), while BRG1 remained stable but its binding to promoters of osteogenic genes increased. Knockdown of BRD9 or BRG1 sharply reduced calcium deposition, whereas knockdown of PBRM1 and BRD7, on the contrary, enhanced mineralization. The inhibitor I-BRD9 suppressed calcification in a dose-dependent manner. IP-MS showed that under osteogenic stimulation the subunits ARID1A/B (BAF markers) disappear from the complexes, while BRD9 and BRD7 remain, meaning a 'subunit switch' takes place. Cut&Run-Seq identified 250 target genes of ncBAF, enriched in TNFα/NF-κB, apoptosis, and glycolysis pathways. Among them was ETS2 itself, which also interacted with the complex. Knockdown of ETS2 suppressed calcification and the expression of BMP2 and RUNX2. In single-nucleus data, VSMCs with co-activation of ETS2 and BRG1 were located in cluster 6, which precedes the terminal osteogenic-inflammatory cluster 8. Spatial transcriptomics showed that osteogenic VSMCs are concentrated in areas rich in macrophages. Immunohistochemistry revealed a positive correlation between ETS2 levels and the degree of calcification (by von Kossa) in 16 aortic samples.
This work is the first to show that subunit switching within SWI/SNF complexes is not a side effect but a necessary condition for launching the osteogenic program in VSMCs. Unlike neighboring studies that describe individual markers or physical aspects of cell mechanics, here a complete chain is built: external mineral stress → activation of ncBAF → expression of ETS2 → cooperative activation of inflammation and osteogenesis genes. This links epigenetics to cell fate at the level of specific transcription factors. The results explain why BRD9 inhibitors may be effective in the early stages of calcification, before irreversible deposits appear.
The topic could move toward testing the ETS2–ncBAF axis in animal models of chronic kidney disease and atherosclerosis. It would be interesting to find out which specific signals from macrophages trigger the subunit switch in VSMCs. It may be possible to develop more selective BRD9 inhibitors that do not affect other bromodomain proteins. A separate question is whether epigenetic priming is reversible: can cells be returned to a contractile phenotype if the complex is blocked in time?
The results will influence cardiology and nephrology, where vascular calcification remains an unsolved problem. They are also important for oncology, since SWI/SNF complexes are known as tumor suppressors, and understanding their tissue-specific roles will help avoid side effects during therapy.
Test the therapeutic effect of BRD9 inhibitors in mouse models of calcification. Study how the plaque microenvironment (macrophages, cytokines) affects the composition of SWI/SNF complexes in VSMCs.
For the field of vascular biology, the key unsolved problem is which epigenetic events are the cause and which are the consequence of the VSMC phenotypic switch. This work shows that ncBAF activation and ETS2 expression precede the appearance of osteogenic markers, meaning they may be early drivers. It remains an open question why cells calcify in some parts of the vessel and not in others, and what role hemodynamics plays in that choice.
The protein BRD9 is named after its bromodomain, a pocket that recognizes acetylated lysines on histones. The inhibitor I-BRD9 occupies this pocket like a key inserted into a lock, preventing the complex from landing on chromatin.
The idea of 'reprogramming' cells in an adult body recalls the plot of the movie Total Recall, where implanted memories change a person's identity. Here an epigenetic complex changes the cell's 'memory' of its profession, forcing a contractile cell to become a bone builder.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.